Nanjing Ningdan New Drug Technology
A company developing new drugs for central nervous system diseases
About Nanjing Ningdan New Drug Technology
Nanjing Ningdan New Drug Technology Co., Ltd., also known as Neurondawn, is a clinical-stage biopharmaceutical company established in December 2020. The company was founded by Chairman and CEO, Yang Shibao, and co-founder Chen Rong. Yang Shibao is noted as the inventor and project leader for the Class 1 new drug, Xianbixin®, and previously held the position of project director at Simcere Pharmaceutical, where he led the development of seven new drug varieties. Chen Rong holds a Ph.D. in Medicinal Chemistry from China Pharmaceutical University and has extensive experience in drug research and development.
The firm concentrates its efforts on developing novel drugs for central nervous system (CNS) diseases, aiming to provide effective solutions for patients with conditions like stroke, Alzheimer's disease, and depression. Neurondawn operates on a research and development-driven business model, focusing on the entire lifecycle of drug development from discovery to commercialization. Its revenue generation is anticipated from the successful development and subsequent marketing of its pipeline products, as well as potential partnerships and collaborations within the pharmaceutical industry. The company serves patients globally who are affected by CNS disorders.
Neurondawn possesses a comprehensive in-house research and development platform that covers drug chemistry synthesis, compound screening, CMC (Chemistry, Manufacturing, and Controls) development, and clinical research. The company has built a robust pipeline of CNS drug candidates. This includes a sublingual formulation of Xianbixin®, developed in collaboration with Simcere Pharmaceutical, which has been submitted for marketing approval and received a "Breakthrough Therapy Designation" from the U.S. FDA. The pipeline also features several other projects at various stages of clinical and preclinical research, such as Y-1 for Alzheimer's and brain tumors, Y-2 for stroke, and Y-3 for stroke and post-stroke depression. Neurondawn has established several key technology platforms, including the ND-S® sublingual formulation platform, the ND-M® multi-target drug development platform, and the ND-C® combination drug platform.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 17.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Nov 2024 | $28M | $110M | Fujian Huaxing Venture Capital | ↗ |
| EARLY VCOther financing | Nov 2023 | $0 | — | Tencent | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nanjing Ningdan New Drug Technology in its local ecosystem
The Nanjing Ningdan New Drug Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Simcere Pharma
China Merchants Health
Tencent
Series B and later1 investor entered at this stage
- FCFujian Huaxing Venture Capital
Other known investors1 additional known investor
- NUNanjing Medical University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nanjing Ningdan New Drug Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nanjing Ningdan New Drug Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









